Experience and challenges for biologic use in the treatment of moderate-to-severe psoriasis in Africa and the Middle East region.

about

Unmet Needs in the Field of Psoriasis: Pathogenesis and Treatment.

P2860

Q53123754-6BB9BE9C-36D7-4FEC-988E-D364400EB3D8

P2860

Experience and challenges for biologic use in the treatment of moderate-to-severe psoriasis in Africa and the Middle East region.

Item

http://www.wikidata.org/entity/Q38838470

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Experience and challenges for ...... ca and the Middle East region.

@en

type

Item

label

Experience and challenges for ...... ca and the Middle East region.

@en

prefLabel

Experience and challenges for ...... ca and the Middle East region.

@en

P1476

Experience and challenges for ...... ica and the Middle East region

@en

P2093

Abdul-Ghani Kibbi

http://www.w3.org/2001/XMLSchema#string

Afaf Al-Sheikh

http://www.w3.org/2001/XMLSchema#string

Alfred Ammoury

http://www.w3.org/2001/XMLSchema#string

Anwar Al Hammadi

http://www.w3.org/2001/XMLSchema#string

Issam Hamadah

http://www.w3.org/2001/XMLSchema#string

Khalid Shirazy

http://www.w3.org/2001/XMLSchema#string

Samer Ghosn

http://www.w3.org/2001/XMLSchema#string

P2860

Definition of treatment goals for moderate to severe psoriasis: a European consensus

Psoriasis: epidemiology, clinical features, and quality of life

Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis

A patient-centred approach to biological treatment decision making for psoriasis: an expert consensus

Psoriatic arthritis in Sub-Saharan Africa.

Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT)

Cost-effectiveness of psoriasis therapy with etanercept in Germany.

Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phas

Quality of type 2 diabetes management in the states of the Co-operation Council for the Arab States of the Gulf: a systematic review.

Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry.

P304

129-135

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1080/09546634.2016.1183763

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Paolo Gisondi

P577

2016-05-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27196814

http://www.w3.org/2001/XMLSchema#string

P921

Middle East

Experience and challenges for biologic use in the treatment of moderate-to-severe psoriasis in Africa and the Middle East region.

about

P2860

P2860

Experience and challenges for biologic use in the treatment of moderate-to-severe psoriasis in Africa and the Middle East region.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921